{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:45:55Z","timestamp":1789580755685,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473955,82173842"],"award-info":[{"award-number":["82473955,82173842"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41417-026-01000-3","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:41:46Z","timestamp":1769064106000},"page":"248-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploration of the mechanism of anlotinib in reversing PD-1 immunotherapy resistance: insights from single-cell sequencing"],"prefix":"10.1038","volume":"33","author":[{"given":"Wanjin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-860X","authenticated-orcid":false,"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-6375","authenticated-orcid":false,"given":"Xiaoman","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-4974","authenticated-orcid":false,"given":"Lufeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"1000_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1000_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/25310429.2025.2457856","volume":"31","author":"I Surovtsova","year":"2025","unstructured":"Surovtsova I, Herth FJF, Kokh DB, Morakis P. Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: real-world evidence. Pulmonology. 2025;31:2457856.","journal-title":"Pulmonology"},{"key":"1000_CR3","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192\u2013iv237.","journal-title":"Ann Oncol"},{"key":"1000_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586\u201397.","journal-title":"J Clin Oncol"},{"key":"1000_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.704336","volume":"11","author":"W Xiong","year":"2021","unstructured":"Xiong W, Zhao Y, Du H, Guo X. Current status of immune checkpoint inhibitor immunotherapy for lung cancer. Front Oncol. 2021;11:704336.","journal-title":"Front Oncol"},{"key":"1000_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.","journal-title":"Mol Cancer"},{"key":"1000_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.18433\/J30033","volume":"19","author":"N Petrovic","year":"2016","unstructured":"Petrovic N. Targeting angiogenesis in cancer treatments: where do we stand? J Pharm Pharm Sci. 2016;19:226\u201338.","journal-title":"J Pharm Pharm Sci"},{"key":"1000_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.","journal-title":"Mol Cancer"},{"key":"1000_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","volume":"38","author":"L Liang","year":"2019","unstructured":"Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res. 2019;38:71.","journal-title":"J Exp Clin Cancer Res"},{"key":"1000_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106668","volume":"188","author":"T Lei","year":"2023","unstructured":"Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C, et al. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis. Pharmacol Res. 2023;188:106668.","journal-title":"Pharmacol Res"},{"key":"1000_CR11","doi-asserted-by":"publisher","first-page":"e21072","DOI":"10.1200\/JCO.2021.39.15_suppl.e21072","volume":"39","author":"B Han","year":"2021","unstructured":"Han B, Chen J, Wang Z, Li X, WANG L, Wu L, et al. Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2021;39:e21072.","journal-title":"J Clin Oncol"},{"key":"1000_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1738","volume":"14","author":"F Song","year":"2024","unstructured":"Song F, Hu B, Liang XL, Cheng JW, Wang CG, Wang PX, et al. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8(+) T-cell infiltration in hepatocellular carcinoma. Clin Transl Med. 2024;14:e1738.","journal-title":"Clin Transl Med"},{"key":"1000_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304.","journal-title":"Nat Biotechnol"},{"key":"1000_CR14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289\u201396.","journal-title":"Nat Methods"},{"key":"1000_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, Klinger B, Kl\u00fcnemann M, Sieber A, Uhlitz F, Sauer S, et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9:20.","journal-title":"Nat Commun"},{"key":"1000_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02581-y","volume":"23","author":"SC Zheng","year":"2022","unstructured":"Zheng SC, Stein-O\u2019Brien G, Augustin JJ, Slosberg J, Carosso GA, Winer B, et al. Universal prediction of cell-cycle position using transfer learning. Genome Biol. 2022;23:41.","journal-title":"Genome Biol"},{"key":"1000_CR17","doi-asserted-by":"crossref","unstructured":"Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14:979\u2013982.","DOI":"10.1038\/nmeth.4402"},{"key":"1000_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12:134\u201353.","journal-title":"Cancer Discov"},{"key":"1000_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"1000_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1000_CR21","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"1000_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51649-3","volume":"15","author":"PB Nicol","year":"2024","unstructured":"Nicol PB, Paulson D, Qian G, Liu XS, Irizarry R, Sahu AD. Robust identification of perturbed cell types in single-cell RNA-seq data. Nat Commun. 2024;15:7610.","journal-title":"Nat Commun"},{"key":"1000_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati GS, Sikandar SS, Wesche DJ, Manjunath A, Bharadwaj A, Berger MJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020;367:405\u201311.","journal-title":"Science"},{"key":"1000_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol. 2024;13:39.","journal-title":"Exp Hematol Oncol"},{"key":"1000_CR25","doi-asserted-by":"publisher","first-page":"e29385","DOI":"10.1371\/journal.pone.0029385","volume":"7","author":"A Laatsch","year":"2012","unstructured":"Laatsch A, Panteli M, Sornsakrin M, Hoffzimmer B, Grewal T, Heeren J. Low density lipoprotein receptor-related protein 1 dependent endosomal trapping and recycling of apolipoprotein E. PLoS One. 2012;7:e29385.","journal-title":"PLoS One"},{"key":"1000_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05322-1","volume":"9","author":"F Bonacina","year":"2018","unstructured":"Bonacina F, Coe D, Wang G, Longhi MP, Baragetti A, Moregola A, et al. Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. Nat Commun. 2018;9:3083.","journal-title":"Nat Commun"},{"key":"1000_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clim.2011.09.011","volume":"142","author":"F Cedeno-Laurent","year":"2012","unstructured":"Cedeno-Laurent F, Dimitroff CJ. Galectin-1 research in T cell immunity: past, present and future. Clin Immunol. 2012;142:107\u201316.","journal-title":"Clin Immunol"},{"key":"1000_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022;28:793\u2013809.","journal-title":"Clin Cancer Res"},{"key":"1000_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.100984","volume":"14","author":"X Han","year":"2024","unstructured":"Han X, Liu J, Zhang Y, Tse E, Yu Q, Lu Y, et al. Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA\/ROCK signalling pathway. J Pharm Anal. 2024;14:100984.","journal-title":"J Pharm Anal"},{"key":"1000_CR30","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1007\/s10238-023-01229-4","volume":"23","author":"SO Imodoye","year":"2023","unstructured":"Imodoye SO, Adedokun KA. EMT-induced immune evasion: connecting the dots from mechanisms to therapy. Clin Exp Med. 2023;23:4265\u201387.","journal-title":"Clin Exp Med"},{"key":"1000_CR31","doi-asserted-by":"crossref","unstructured":"Gialeli C, Fountas P, Shami A, Sun J, Bocci M, Nitulescu M et al. The extracellular matrix proteoglycan serglycin is associated with human atherosclerotic plaque inflammation. Cardiovasc Res. 2024;120:cvae088.181.","DOI":"10.1093\/cvr\/cvae088.181"},{"key":"1000_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152821","volume":"229","author":"R Huo","year":"2024","unstructured":"Huo R, Zhao R, Li Z, Li M, Bin Y, Wang D, et al. APOE expression in papillary thyroid carcinoma: influencing tumor progression and macrophage polarization. Immunobiology. 2024;229:152821.","journal-title":"Immunobiology"},{"key":"1000_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03765-3","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Chen C, Han M, Tian C, Song F, Feng S, et al. CXCL2: a key player in the tumor microenvironment and inflammatory diseases. Cancer Cell Int. 2025;25:133.","journal-title":"Cancer Cell Int"},{"key":"1000_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121527","volume":"616","author":"D Liu","year":"2022","unstructured":"Liu D, Gao S, Zhai Y, Yang X, Zhai G. Research progress of tumor targeted drug delivery based on PD-1\/PD-L1. Int J Pharm. 2022;616:121527.","journal-title":"Int J Pharm"},{"key":"1000_CR35","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24:1260\u201370.","journal-title":"Clin Cancer Res"},{"key":"1000_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72\u201381.","journal-title":"Cancer Lett"},{"key":"1000_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semcancer.2022.07.004","volume":"86","author":"J Pouyss\u00e9gur","year":"2022","unstructured":"Pouyss\u00e9gur J, Marchiq I, Parks SK, Durivault J, \u017ddralevi\u0107 M, Vucetic M. \u2018Warburg effect\u2019 controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives. Semin Cancer Biol. 2022;86:334\u201346.","journal-title":"Semin Cancer Biol"},{"key":"1000_CR38","first-page":"127","volume":"350","author":"A Yoshimura","year":"2011","unstructured":"Yoshimura A, Muto G. TGF-\u03b2 function in immune suppression. Curr Top Microbiol Immunol. 2011;350:127\u201347.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1000_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8:31.","journal-title":"NPJ Precis Oncol"},{"key":"1000_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY, Dong Y, Ma YY, Wang W, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updat. 2023;66:100907.","journal-title":"Drug Resist Updat"},{"key":"1000_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113944","volume":"147","author":"Z Huang","year":"2025","unstructured":"Huang Z, Li Y, Liu Q, Chen X, Lin W, Wu W, et al. SPP1-mediated M2 macrophage polarization shapes the tumor microenvironment and enhances prognosis and immunotherapy guidance in nasopharyngeal carcinoma. Int Immunopharmacol. 2025;147:113944.","journal-title":"Int Immunopharmacol"},{"key":"1000_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13046-020-01763-z","volume":"39","author":"Z Xue","year":"2020","unstructured":"Xue Z, Lui VWY, Li Y, Jia L, You C, Li X, et al. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2020;39:262.","journal-title":"J Exp Clin Cancer Res"},{"key":"1000_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176639","volume":"975","author":"Y Lu","year":"2024","unstructured":"Lu Y, Han X, Zhang H, Zheng L, Li X. Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism. Eur J Pharmacol. 2024;975:176639.","journal-title":"Eur J Pharmacol"},{"key":"1000_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11:309.","journal-title":"Cell Death Dis"},{"key":"1000_CR45","unstructured":"Zavacky E. Investigating the heterogeneity of tumour-associated macrophages in renal cell carcinoma milieu. Montreal, Quebec, Canada; McGill University: 2023."},{"key":"1000_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/03008207.2024.2380313","volume":"65","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li Z, Chen C, Wei W, Li Z, Zhou H, et al. SRGN promotes macrophage recruitment through CCL3 in osteoarthritis. Connect Tissue Res. 2024;65:330\u201342.","journal-title":"Connect Tissue Res"},{"key":"1000_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06849-7","volume":"20","author":"X Wang","year":"2020","unstructured":"Wang X, Xiong H, Liang D, Chen Z, Li X, Zhang K. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients. BMC Cancer. 2020;20:378.","journal-title":"BMC Cancer"},{"key":"1000_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L. Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol. 2022;13:888713.","journal-title":"Front Immunol"},{"key":"1000_CR49","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3389\/fimmu.2018.01930","volume":"9","author":"P Ruytinx","year":"2018","unstructured":"Ruytinx P, Proost P, Van Damme J, Struyf S. Chemokine-induced macrophage polarization in inflammatory conditions. Front Immunol. 2018;9:1930.","journal-title":"Front Immunol"},{"key":"1000_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594609","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Guan XY, Jiang P. Cytokine and chemokine signals of T-cell exclusion in tumors. Front Immunol. 2020;11:594609.","journal-title":"Front Immunol"},{"key":"1000_CR51","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.chom.2025.04.022","volume":"33","author":"M Zhang","year":"2025","unstructured":"Zhang M, Wei Z, Wei B, Lai C, Zong G, Tao E, et al. Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. Cell Host Microbe. 2025;33:915\u201331.e9.","journal-title":"Cell Host Microbe"},{"key":"1000_CR52","doi-asserted-by":"publisher","first-page":"e009165","DOI":"10.1136\/jitc-2024-009165","volume":"12","author":"C Lu","year":"2024","unstructured":"Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. J Immunother Cancer. 2024;12:e009165.","journal-title":"J Immunother Cancer"},{"key":"1000_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1951019","volume":"10","author":"Y Fang","year":"2021","unstructured":"Fang Y, Wang Y, Zeng D, Zhi S, Shu T, Huang N, et al. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR\/ALK-positive non-small-cell lung cancer. Oncoimmunology. 2021;10:1951019.","journal-title":"Oncoimmunology"},{"key":"1000_CR54","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9:eaak9679.","journal-title":"Sci Transl Med"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01000-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:03:00Z","timestamp":1771455780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01000-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01000-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7277840\/v1","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal studies were conducted in strict compliance with guidelines and protocols submitted to and approved by the Animal Welfare and Ethics Committee (AWEC) of China Pharmaceutical University (approval number: 2024-08-003), in adherence to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}